Objective and Subjective Outcome of a New Transcutaneous Bone Conduction Hearing Device

Eberhard, Kristine Elisabeth; Olsen, Steen Østergaard; Miyazaki, Hiroyuki; Bille, Mikkel; Cayé‐Thomasen, Per

doi:10.1097/mao.0000000000000969

Cited by 23 publications

(38 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To our knowledge, only two comparable studies reported results on the SSQ questionnaires in patients treatet with this BCD: Laske et al used the SSQ49-B (scale from -5 to +5) and Eberhard et al used the SSQ12-A (scale from 1 to 10) [ 12 , 13 ]. Laske et al reported that for a patient cohort with single-sided-deafness (SSD), the “speech”component scored highest, while there was little improvement (close to 0) in the “spatial hearing”and “hearing qualities”subcategories [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

Patient-reported long-term benefit with an active transcutaneous bone-conduction device

2020

View full text Add to dashboard Cite

Purpose To evaluate the long-term benefits in hearing-related quality of life, patient satisfaction and wearing time of patients rehabilitated with an active transcutaneous bone-conduction device. Adverse events and audiological outcomes are reported as secondary outcomes. Methods This retrospective, mono-centric cohort analysis involves 16 adults with conductive or mixed hearing loss with a mean device experience of 51.25 months. Patient-reported outcome measures were assessed using the short version of the Speech, Spatial and Qualities of Hearing Scale (SSQ12-B) and the German version of the Audio Processor Satisfaction Questionnaire (APSQ). Audiological outcomes as well as incidence of adverse events were obtained from patients´ charts. Results The hearing-related quality of life improved significantly within all subscales of the SSQ12-B scoring a mean overall of 2.95 points. Patient satisfaction measured with the APSQ scored 8.8 points on average. Wearing times differed considerably and patients with lower levels of education seemed to use their device longer compared to patients with academic education. Eight minor adverse events were documented, all of which resolved during follow-up. The mean gain in word recognition score at the last follow-up measured at 65 dB was 75.9%, while speech reception threshold was lowered by 35.1 dB. Conclusion Even after several years, patients report significant benefits in hearing-related quality of life and device satisfaction. In combination with a low rate of minor adverse events and significantly improved audiological outcomes, the device is considered as a comfortable and effective option in hearing rehabilitation.

show abstract

Section: Discussionmentioning

confidence: 99%

Patient-reported long-term benefit with an active transcutaneous bone-conduction device

2020

View full text Add to dashboard Cite

show abstract

“…Results from other similar studies are of interest, and especially comparisons with the commercially available active transcutaneous Bone Bridge (Med El). The selected comparative studies are chosen with the criteria that both tone and speech audiometry are performed in unaided and aided conditions and where at least 6 or more subjects are included [Ihler et al, 2014;Rahne and Ehelebe, 2014;Riss et al, 2014;Eberhard et al, 2016;Gerdes et al, 2016;Ihler et al, 2016;Schmerber et al, 2017]. Different methods have been applied concerning indication for the Bone Bridge, number of subjects, tone and speech audiometry, follow-up time, and the presentation of questionnaires.…”

Section: Comparison With Other Studiesmentioning

confidence: 99%

“…Surgery is generally without complications, and there are no reports of serious skin problems. Among the selected comparative studies, the skin in the surgical area is evaluated and described in 3 studies [Ihler et al, 2014;Eberhard et al, 2016;Schmerber et al, 2017], where there are 2 cases with postoperative wound healing resolved using only antibiotics in one case, and by both antibiotics and a minor surgical intervention in one case.…”

Section: Comparison With Other Studiesmentioning

confidence: 99%

Three-Year Follow-Up with the Bone Conduction Implant

et al. 2020

View full text Add to dashboard Cite

Background: The bone conduction implant (BCI) is an active transcutaneous bone conduction device where the transducer has direct contact to the bone, and the skin is intact. Sixteen patients have been implanted with the BCI with a planned follow-up of 5 years. This study reports on hearing, quality of life, and objective measures up to 36 months of follow-up in 10 patients. Method: Repeated measures were performed at fitting and after 1, 3, 6, 12, and 36 months including sound field warble tone thresholds, speech recognition thresholds in quiet, speech recognition score in noise, and speech-to-noise thresholds for 50% correct words with adaptive noise. Three quality of life questionnaires were used to capture the benefit from the intervention, appreciation from different listening situations, and the ability to interact with other people when using the BCI. The results were compared to the unaided situation and a Ponto Pro Power on a soft band. The implant functionality was measured by nasal sound pressure, and the retention force from the audio processor against the skin was measured using a specially designed audio processor and a force gauge. Results: Audiometry and quality of life questionnaires using the BCI or the Ponto Pro Power on a soft band were significantly improved compared to the unaided situation and the results were statistically supported. There was generally no significant difference between the two devices. The nasal sound pressure remained stable over the study period and the force on the skin from the audio processor was 0.71 ± 0.22 N (mean ± 1 SD). Conclusion: The BCI improves the hearing ability for tones and speech perception in quiet and in noise for the indicated patients. The results are stable over a 3-year period, and the patients subjectively report a beneficial experience from using the BCI. The transducer performance and contact to the bone is unchanged over time, and the skin area under the audio processor remains without complications during the 3-year follow-up.

show abstract

“…This approach not only eliminates the cosmetic concerns that patients have with an abutment but also the need for a meticulous cleaning of the abutment site and associated wound issues . An analogously magnetically coupled bone conduction device (Baha Attract Band, Cochlear Bone‐Anchored Solutions)) has since been introduced, along with a novel bone conduction device employing an internal floating mass transducer that is positioned in the mastoid or retromastoid area (Bonebridge, Med‐El) . Preliminary data on the first 12 patients with this new device (and 6 months follow‐up) are very limited.…”

Section: Literature Reviewmentioning

confidence: 99%

“…3 An analogously magnetically coupled bone conduction device (Baha Attract Band, Cochlear Bone-Anchored Solutions)) has since been introduced, along with a novel bone conduction device employing an internal floating mass transducer that is positioned in the mastoid or retromastoid area (Bonebridge, Med-El). 4 Preliminary data on the first 12 patients with this new device (and 6 months follow-up) are very limited. Initially, MRI was contraindicated for patients with magnetic implants.…”

Section: Literature Reviewmentioning

confidence: 99%